This program is kindly supported by

Our supporters part sponsored the meeting. Our supporters had no influence or input in the event.

Course curriculum

    1. Dr. Hagop Kantarjian - Research and Progress in AML

    2. Dr. Paresh Vyas - Practical Approach to Incorporating Genomics in Treatment Decision Making in Fit Adult AML

    3. Dr. Christoph Röllig - Incorporating MRD into Treatment Decision Making in Newly Diagnosed AML, Focus on NPM1 and FLT3 Mutated AML

    4. Dr. Priyanka Mehta - Current Status and Updates in the Diagnosis, Prognosis and Management of Secondary and Therapy Related AML

    5. Dr. Charlie Craddock - Optimising Transplant Outcomes in High-risk AML?

    6. Panel Discussion

    1. Dr. Ilaria Iacobucci - Biology of Ph Pos ALL: New Insights for a Risk Stratification?

    2. Dr. Elias Jabbour - How I Treat Ph Positive ALL in 2024: US

    3. Dr. Robin Foà - How I Treat Ph Positive ALL in 2024: Europe

    4. Dr. Emmanuelle Clappier - SCT in Ph+ ALL: is it Still Necessary?

    5. Dr. Rob Pieters - Open Issues in Pediatric ALL

    6. Panel Discussion

    1. Dr. Naval Daver - Which Patients with Newly Diagnosed AML Should Receive a Venetoclax Based Regimen in 2024

    2. Dr. Emma Searle - Menin Inhibitors in the Management of AML

    3. Dr. Marion Subklewe - Immunotherapeutic Strategies in AML

    4. Dr. Alessandro Isidori - Management of Disease Relapse in Fit and Unfit AML Patients

    5. Panel Discussion

    1. Dr. Anna Castleton - SCT in Adult Ph Neg ALL: How, When and for Which Patients?

    2. Dr. Marion Subklewe - CAR-T Cells in ALL: Progress and Pitfalls

    3. Dr. Claire Roddie - Debate: R/R Ph Neg ALL: CAR-T Cells or Antibodies? - CAR-T Cells

    4. Dr. Nicolas Boissel - Debate: R/R Ph Neg ALL: CAR-T Cells or Antibodies? - Antibodies

    5. Panel & Debate Discussion

    1. Dr. Stephane De Botton - Evolving Front-line Treatment Options and Treatment Journey in FLT3 Mutated AML Patients Eligible for Intensive Chemotherapy

    2. Dr. Maria Teresa Voso - Treatment of APML in 2024

    3. Dr. Pramila Krishnamurthy - Addressing Inequity of Outcomes and Accessing Patients with AML

    4. Dr. Michael Dennis - Optimising Outcomes and Practical Pointers in Patients Treated with HMA+venetoclax Based Regimen

    5. Panel Discussion

    1. Dr. Monika Brüggemann - MRD in ALL: How can we Measure it?

    2. Dr. Cristina Papayannidis - Treatment Strategies to Eradicate MRD

    3. Dr. Giovanni Martinelli - Treatment Strategies in Ph Like ALL

    4. Panel Discussion

    5. Dr. Anna Castleton - First Line Approaches in Ph Neg ALL in 2024 - AYA

    6. Dr. Sabina Chiaretti - First Line Approaches in Ph Neg ALL in 2024 - Adult

    7. Dr. Elias Jabbour - First Line Approaches in Ph Neg ALL in 2024 - Elderly

    8. Panel Discussion

About this course

  • Free
  • 46 lessons
  • 14 hours of video content

Join us in-person for AML-ALL EU 2025

October 24 - 25, 2025 Athens, Greece

Get started now

Video